Sanofi SA (SAN) Given a €87.00 Price Target at Jefferies Group LLC
A number of other brokerages also recently commented on SAN. Deutsche Bank AG set a €96.00 ($112.94) price target on Sanofi SA and gave the company a buy rating in a report on Tuesday, May 2nd. J P Morgan Chase & Co set a €95.00 ($111.76) price target on Sanofi SA and gave the company a neutral rating in a report on Thursday, June 22nd. UBS AG set a €82.00 ($96.47) price target on Sanofi SA and gave the company a neutral rating in a report on Friday, April 28th. Berenberg Bank set a €97.00 ($114.12) price target on Sanofi SA and gave the company a neutral rating in a report on Saturday, May 20th. Finally, Goldman Sachs Group, Inc. (The) set a €82.00 ($96.47) price target on Sanofi SA and gave the company a neutral rating in a report on Tuesday, May 2nd. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and five have given a buy rating to the stock. Sanofi SA currently has an average rating of Hold and a consensus target price of €87.44 ($102.87).
Sanofi SA (EPA SAN) traded down 0.17% during mid-day trading on Thursday, reaching €82.10. 1,039,692 shares of the company were exchanged. The stock has a market capitalization of €103.10 billion and a price-to-earnings ratio of 11.45. Sanofi SA has a 1-year low of €62.50 and a 1-year high of €92.97. The stock’s 50-day moving average price is €25.48 and its 200-day moving average price is €25.74.
Sanofi SA Company Profile
Sanofi researches, develops, manufactures, and markets therapeutic solutions. The company operates in two segments, Pharmaceuticals and Vaccines. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an oral immunomodulatory and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Receive News & Stock Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related stocks with our FREE daily email newsletter.